Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Pharmaceuticals has introduced generic version of Sofosbuvir 400mg tablets in India under the brand name MyHep.
Subscribe to our email newsletter
The tablets are indicated to treat chronic hepatitis C, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen.
The virus affects over 100 million people in the developing world, including around 12 million people who are chronically infected with hepatitis C in India.
Mylan has non-exclusive rights to manufacture and distribute generic Sofosbuvir in 91 developing countries, including India.
The company secured product rights from Gilead under a licensing and technology transfer agreement signed by the two firms in September 2014.
Mylan president Rajiv Malik said: "The launch of Mylan’s MyHep offers hope to millions of hepatitis C patients in India who are in need of a high quality, effective and affordable treatment option.
"We look forward to bringing that same hope to millions of more hepatitis C patients as we expand access to MyHep in the developing world."
The company said that MyHep is an important addition to its growing commercial business in India and is sold by its dedicated sales force as part of its Hepato Care segment.
Image: Mylan generic Sofosbuvir 400mg tablets. Photo: courtesy of Mylan N.V.